The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×2•Originally published 6 May 2026•Updated 8 May 2026•

1 min read

Class Action Lawsuits Filed Against Gemini Space Station and ImmunityBio Over Misleading Claims

Key Facts

1Gemini Space Station (GEMI) faces a lawsuit alleging the concealment of a corporate pivot and executive turmoil in its IPO documents.

2GEMI stock has traded more than 75% below its IPO price following a series of negative disclosures.

26 days ago

Version History

Version 226 days ago

What changed: A new law firm (Bragar Eagel & Squire) has joined the litigation and a specific legal contact has been named for investors.

Version 126 days ago

What changed: Added a 10-day legal deadline for shareholders, identified Cameron and Tyler Winklevoss as defendants, and confirmed the NASDAQ listing.

Gemini Space Station and ImmunityBio are facing securities class action lawsuits alleging violations of federal securities laws on the NASDAQ exchange. The litigation against Gemini Space Station (GEMI) cites concealed corporate pivots that led to a 75% drop in stock value from its IPO price. In a recent update, the law firm Bragar Eagel & Squire has joined the legal efforts against Gemini, with attorney Brandon Walker identified as the primary contact for affected investors. Simultaneously, ImmunityBio (IBRX) remains under scrutiny following an FDA warning regarding its drug, Anktiva. A critical 10-day deadline remains in place for impacted investors to join the legal action and seek recovery for their losses. These developments underscore the intensifying regulatory and legal risks facing both entities.